Guest guest Posted September 19, 2009 Report Share Posted September 19, 2009 Awwww, I am so sorry, hoping you soon feel better, we've missed you! from Jules: as we move closer to having oral HCV drugs we move closer to all patient types getting cured of HCV. There are at least 20-25 new orally administered HCV drugs in development and companies are looking at various strategies to limit or eliminate use of side-effect associated interferon and ribavirin. I predict that within 10 years maybe 7 we will be close to 100% cure rates in HCV for all types of patients including coinfected African-Americans because the response to oral drugs is the same for all, caucasians and African-Americans. We will have HCV drug regimens consisting of multiple drugs, as many as 3-4 drugs. Most drug company have at least 2 oral drugs in development and some are trying to acquire more, and the companies are racing to beat each other to market. National AIDS Treatment Advocacy Project - NATAP - HIV - AIDS Hepatitis Treatment Information EASL 44th Annual Meeting (European Association for the Study of the Liver)April 22-26, 2009Copenhagen, Denmark Roche INFORM Study slides at EASL 2009: Potent Antiviral Activity With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN- 191) Inhibitor Combination in HCV Genotype 1: Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (04/28/09) Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09) HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral activity - (04/28/09) EASL Analysis, New Oral HCV Drugs What's Expected - (05/14/09) Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C - (04/28/09) Ground-Breaking Combination of 2 All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) - (04/28/09) Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C - (04/28/09) New HCV Drug Report: "Using a new palette of treatment options to paint the portrait of cure for patients infected with hepatitis C on our clinical canvas." - written by Gish MD - (05/28/09) R7128 These are selected results from doing Search on NATAP website (NATAP Search Engine): Pharmasset Presents Results of 4-Week Combination Study of R7128 ... Apr 25, 2008 ... 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys® plus Copegus® - ...www.natap.org/ 2008/EASL/ EASL_27.htm Pharmasset Presents R7128 14-Day Monotherapy Study Results for the ... Nov 2, 2007 ... R7128 is an orally administered prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of hepatitis C virus (HCV) that is ...www.natap.org/ 2007/AASLD/ AASLD_02. htm Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response ... 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment withR7128 1500mg and Pegasys® plus Copegus® with safety and ...www.natap.org/ 2008/HCV/ 010708_01. htm Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of ... R7128 was generally well-tolerated and demonstrated no evidence of acute target ... 78% of subjects receiving R7128 with abnormal ALT at baseline normalized ...www.natap.org/ 2007/AASLD/ AASLD_30. htm Potent Antiviral Response To The HCV Nucleoside Polymerase ... Nov 1, 2008 ... R7128 has demonstrated that short-term treatment with a potent ...Background: R7128 is a potent nucleoside analog inhibitor of HCV ...www.natap.org/ 2008/AASLD/ AASLD_22. htm Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor ... Nov 1, 2008 ... Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCVGenotype 2 and 3 Prior Non-Responders: Results Of R7128 1500mg ...www.natap.org/ 2008/AASLD/ AASLD_20. htm Pharmasset Reports Preliminary Results of a 4-week Proof-of ... 90% of genotype 2 or 3 patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys® plus Copegus® ...www.natap.org/ 2008/HCV/ 091508_02. htm Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study Apr 24, 2008 ... Two 4-week cohorts will be enrolled to evaluate R7128 1500mg BID in HCVgenotypes 2 and 3 prior non-responders and R7128 1000mg BID in HCV ...www.natap.org/ 2008/EASL/ EASL_26.htm Potent Antiviral Response To The HCV Nucleoside Polymerase ... Nov 1, 2008 ... In Cohort 2 (R7128 1500mg BID) RVR rates were 90% for the Caucasian subjects, ... HCV genotype, Weight, BMI and gender were not significant ...www.natap.org/ 2008/AASLD/ AASLD_22.htm Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.